Dynamic PSA trajectories during neoadjuvant hormonal therapy are associated with event-free survival after radical prostatectomy in prostate cancer: a latent class growth mixture modeling analysis

PURPOSE: Prostate-specific antigen (PSA) kinetics during neoadjuvant hormonal therapy (NHT) may provide prognostic information for patients undergoing radical prostatectomy (RP), but previous studies have relied on single summary parameters. This study aimed to identify PSA trajectory classes during NHT using latent class growth mixture modeling (LCGMM) and to evaluate their association with postoperative event-free survival (EFS). METHODS: This single-center retrospective study included 166 patients with prostate cancer who received NHT followed by RP between January 2021 and December 2024. Serial PSA measurements during NHT were analyzed using LCGMM. EFS was defined as the time from RP to biochemical recurrence, local or regional recurrence, distant metastasis, or death. Cox models were adjusted for initial PSA, clinical T stage, ISUP Grade Group, clinical M stage and adjuvant hormonal therapy. Sensitivity analyses addressed disease extent, adjuvant therapy, postoperative PSA persistence and classification uncertainty; internal validation used bootstrapping. RESULTS: Three trajectory classes were identified: slow decline with rebound (33.7%), intermediate sustained decline (44.6%) and rapid-deep decline (21.7%). At a median follow-up of 22.0 months, 2-year EFS rates were 54% (95% CI 38-67%), 80% (68-88%) and 90% (73-97%), respectively (log-rank P = 0.0017). In multivariable analysis, the rapid-deep decline class was associated with a lower risk of events than the slow decline with rebound class (HR 0.16; 95% CI 0.06-0.43; P < 0.001), whereas the intermediate sustained decline class did not differ significantly (HR 0.59; 95% CI 0.31-1.12; P = 0.107). Adding trajectory class improved model fit (likelihood ratio χ² = 17.38, df = 2, P = 0.0002; optimism-corrected C-index 0.741 vs. 0.677). The association for the rapid-deep decline class persisted in cN0M0 patients (HR 0.11; 95% CI 0.03-0.40), after exclusion of patients with postoperative PSA persistence (HR 0.18; 95% CI 0.06-0.49) and in patients without adjuvant hormonal therapy (adjusted HR 0.06; 95% CI 0.01-0.56). CONCLUSION: In this retrospective cohort, PSA trajectory classes during NHT were associated with EFS after RP, mainly reflecting the favorable outcome of patients with a rapid-deep PSA decline. These hypothesis-generating findings require external validation in larger cohorts with longer follow-up before PSA trajectories can be used for risk stratification.

Authors

Institutions

Publication Details

Journal
BMC Urology
Published
2026-11-17
DOI
https://doi.org/10.1186/s12894-026-02403-y
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dynamic PSA trajectories during neoadjuvant hormonal therapy are associated with event-free survival after radical prostatectomy in prostate cancer: a latent class growth mixture modeling analysis

Zongsu Zhang, Simeng Wen, Zhongxian Zhao, Zhaodelong Dai et al.
BMC Urology
Prostate Cancer Diagnosis and Treatment
article

Dynamic PSA trajectories during neoadjuvant hormonal therapy are associated with event-free survival after radical prostatectomy in prostate cancer: a latent class growth mixture modeling analysis

Zongsu Zhang, Simeng Wen, Zhongxian Zhao, Zhaodelong Dai, Ziqi Fang
article en

Abstract

PURPOSE: Prostate-specific antigen (PSA) kinetics during neoadjuvant hormonal therapy (NHT) may provide prognostic information for patients undergoing radical prostatectomy (RP), but previous studies have relied on single summary parameters. This study aimed to identify PSA trajectory classes during NHT using latent class growth mixture modeling (LCGMM) and to evaluate their association with postoperative event-free survival (EFS). METHODS: This single-center retrospective study included 166 patients with prostate cancer who received NHT followed by RP between January 2021 and December 2024. Serial PSA measurements during NHT were analyzed using LCGMM. EFS was defined as the time from RP to biochemical recurrence, local or regional recurrence, distant metastasis, or death. Cox models were adjusted for initial PSA, clinical T stage, ISUP Grade Group, clinical M stage and adjuvant hormonal therapy. Sensitivity analyses addressed disease extent, adjuvant therapy, postoperative PSA persistence and classification uncertainty; internal validation used bootstrapping. RESULTS: Three trajectory classes were identified: slow decline with rebound (33.7%), intermediate sustained decline (44.6%) and rapid-deep decline (21.7%). At a median follow-up of 22.0 months, 2-year EFS rates were 54% (95% CI 38-67%), 80% (68-88%) and 90% (73-97%), respectively (log-rank P = 0.0017). In multivariable analysis, the rapid-deep decline class was associated with a lower risk of events than the slow decline with rebound class (HR 0.16; 95% CI 0.06-0.43; P < 0.001), whereas the intermediate sustained decline class did not differ significantly (HR 0.59; 95% CI 0.31-1.12; P = 0.107). Adding trajectory class improved model fit (likelihood ratio χ² = 17.38, df = 2, P = 0.0002; optimism-corrected C-index 0.741 vs. 0.677). The association for the rapid-deep decline class persisted in cN0M0 patients (HR 0.11; 95% CI 0.03-0.40), after exclusion of patients with postoperative PSA persistence (HR 0.18; 95% CI 0.06-0.49) and in patients without adjuvant hormonal therapy (adjusted HR 0.06; 95% CI 0.01-0.56). CONCLUSION: In this retrospective cohort, PSA trajectory classes during NHT were associated with EFS after RP, mainly reflecting the favorable outcome of patients with a rapid-deep PSA decline. These hypothesis-generating findings require external validation in larger cohorts with longer follow-up before PSA trajectories can be used for risk stratification.

BMC UrologyVol. 26(1)
Second Hospital of Tianjin Medical University (CN), Tianjin Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon